AIM ImmunoTech disclosed that its CEO, Thomas K. Equels, published an article in the online media outlet Breaking Defense. The article advocates for the company's drug, Ampligen (rintatolimod), as a potential broad-spectrum antiviral therapeutic for military biodefense and force protection against viral threats such as Ebola and coronaviruses.
Key Details
- Publication: The article, titled “Biodefense is force protection: Ready today, prepared for tomorrow,” was authored by CEO Thomas K. Equels and published on August 11, 2026.
- Strategic Focus: It positions Ampligen as a potential prophylactic or early-onset treatment to protect military forces from novel viral threats, including Ebola virus disease and COVID-19.
- Supporting Data Cited: The article references prior government-funded preclinical studies, including research at the U.S. Army Medical Research Institute of Infectious Diseases that showed 100% survival in a mouse model of Ebola.